vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and SOMNIGROUP INTERNATIONAL INC. (SGI). Click either name above to swap in a different company.
SOMNIGROUP INTERNATIONAL INC. is the larger business by last-quarter revenue ($1.9B vs $1.1B, roughly 1.6× Elanco Animal Health Inc). SOMNIGROUP INTERNATIONAL INC. runs the higher net margin — 7.5% vs -24.1%, a 31.7% gap on every dollar of revenue. On growth, SOMNIGROUP INTERNATIONAL INC. posted the faster year-over-year revenue change (54.7% vs 12.2%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $41.1M). Over the past eight quarters, SOMNIGROUP INTERNATIONAL INC.'s revenue compounded faster (25.3% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Somnigroup International Inc. is an American manufacturer of mattresses and bedding products.
ELAN vs SGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.9B |
| Net Profit | $-276.0M | $140.8M |
| Gross Margin | 51.5% | 44.0% |
| Operating Margin | -22.6% | 13.2% |
| Net Margin | -24.1% | 7.5% |
| Revenue YoY | 12.2% | 54.7% |
| Net Profit YoY | -3350.0% | 95.8% |
| EPS (diluted) | $-0.55 | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.3B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $-276.0M | $140.8M | ||
| Q3 25 | $-34.0M | $177.4M | ||
| Q2 25 | $11.0M | $99.0M | ||
| Q1 25 | $67.0M | $-33.1M | ||
| Q4 24 | $-8.0M | $71.9M | ||
| Q3 24 | $364.0M | $130.0M | ||
| Q2 24 | $-50.0M | $106.1M | ||
| Q1 24 | $32.0M | $76.3M |
| Q4 25 | 51.5% | 44.0% | ||
| Q3 25 | 53.4% | 44.9% | ||
| Q2 25 | 57.5% | 44.0% | ||
| Q1 25 | 57.3% | 36.2% | ||
| Q4 24 | 50.9% | 43.3% | ||
| Q3 24 | 52.2% | 45.4% | ||
| Q2 24 | 58.2% | 44.9% | ||
| Q1 24 | 57.3% | 43.1% |
| Q4 25 | -22.6% | 13.2% | ||
| Q3 25 | -4.4% | 14.8% | ||
| Q2 25 | 2.0% | 9.6% | ||
| Q1 25 | 5.0% | 0.8% | ||
| Q4 24 | -5.0% | 10.6% | ||
| Q3 24 | 54.3% | 15.5% | ||
| Q2 24 | -2.7% | 14.0% | ||
| Q1 24 | 1.0% | 11.1% |
| Q4 25 | -24.1% | 7.5% | ||
| Q3 25 | -3.0% | 8.4% | ||
| Q2 25 | 0.9% | 5.3% | ||
| Q1 25 | 5.6% | -2.1% | ||
| Q4 24 | -0.8% | 6.0% | ||
| Q3 24 | 35.3% | 10.0% | ||
| Q2 24 | -4.2% | 8.6% | ||
| Q1 24 | 2.7% | 6.4% |
| Q4 25 | $-0.55 | $0.71 | ||
| Q3 25 | $-0.07 | $0.83 | ||
| Q2 25 | $0.02 | $0.47 | ||
| Q1 25 | $0.13 | $-0.17 | ||
| Q4 24 | $-0.01 | $0.40 | ||
| Q3 24 | $0.73 | $0.73 | ||
| Q2 24 | $-0.10 | $0.60 | ||
| Q1 24 | $0.06 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | — |
| Total DebtLower is stronger | $3.9B | $4.6B |
| Stockholders' EquityBook value | $6.5B | $3.1B |
| Total Assets | $13.4B | $11.6B |
| Debt / EquityLower = less leverage | 0.60× | 1.47× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | — | ||
| Q4 24 | $468.0M | — | ||
| Q3 24 | $490.0M | — | ||
| Q2 24 | $416.0M | — | ||
| Q1 24 | $345.0M | — |
| Q4 25 | $3.9B | $4.6B | ||
| Q3 25 | $4.0B | $4.5B | ||
| Q2 25 | $4.1B | $4.8B | ||
| Q1 25 | $4.4B | $4.9B | ||
| Q4 24 | $4.3B | $3.7B | ||
| Q3 24 | $4.4B | $2.2B | ||
| Q2 24 | $5.7B | $2.4B | ||
| Q1 24 | $5.8B | $2.5B |
| Q4 25 | $6.5B | $3.1B | ||
| Q3 25 | $6.7B | $3.0B | ||
| Q2 25 | $6.8B | $2.8B | ||
| Q1 25 | $6.4B | $2.7B | ||
| Q4 24 | $6.1B | $559.0M | ||
| Q3 24 | $6.5B | $564.5M | ||
| Q2 24 | $5.9B | $411.8M | ||
| Q1 24 | $6.1B | $326.6M |
| Q4 25 | $13.4B | $11.6B | ||
| Q3 25 | $13.6B | $11.4B | ||
| Q2 25 | $13.7B | $11.4B | ||
| Q1 25 | $12.9B | $11.3B | ||
| Q4 24 | $12.6B | $6.0B | ||
| Q3 24 | $13.3B | $4.6B | ||
| Q2 24 | $13.8B | $4.6B | ||
| Q1 24 | $14.0B | $4.6B |
| Q4 25 | 0.60× | 1.47× | ||
| Q3 25 | 0.59× | 1.51× | ||
| Q2 25 | 0.61× | 1.69× | ||
| Q1 25 | 0.69× | 1.79× | ||
| Q4 24 | 0.70× | 6.69× | ||
| Q3 24 | 0.67× | 3.95× | ||
| Q2 24 | 0.96× | 5.92× | ||
| Q1 24 | 0.95× | 7.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $99.4M |
| Free Cash FlowOCF − Capex | $46.0M | $41.1M |
| FCF MarginFCF / Revenue | 4.0% | 2.2% |
| Capex IntensityCapex / Revenue | 5.4% | 3.1% |
| Cash ConversionOCF / Net Profit | — | 0.71× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $633.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $99.4M | ||
| Q3 25 | $219.0M | $408.2M | ||
| Q2 25 | $237.0M | $186.1M | ||
| Q1 25 | $-4.0M | $106.4M | ||
| Q4 24 | $177.0M | $129.1M | ||
| Q3 24 | $162.0M | $256.6M | ||
| Q2 24 | $200.0M | $150.6M | ||
| Q1 24 | $2.0M | $130.2M |
| Q4 25 | $46.0M | $41.1M | ||
| Q3 25 | $127.0M | $360.3M | ||
| Q2 25 | $180.0M | $149.4M | ||
| Q1 25 | $-69.0M | $82.4M | ||
| Q4 24 | $130.0M | $108.2M | ||
| Q3 24 | $120.0M | $240.2M | ||
| Q2 24 | $166.0M | $122.1M | ||
| Q1 24 | $-22.0M | $98.7M |
| Q4 25 | 4.0% | 2.2% | ||
| Q3 25 | 11.2% | 17.0% | ||
| Q2 25 | 14.5% | 7.9% | ||
| Q1 25 | -5.8% | 5.1% | ||
| Q4 24 | 12.7% | 9.0% | ||
| Q3 24 | 11.7% | 18.5% | ||
| Q2 24 | 14.0% | 9.9% | ||
| Q1 24 | -1.8% | 8.3% |
| Q4 25 | 5.4% | 3.1% | ||
| Q3 25 | 8.1% | 2.3% | ||
| Q2 25 | 4.6% | 2.0% | ||
| Q1 25 | 5.4% | 1.5% | ||
| Q4 24 | 4.6% | 1.7% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 2.9% | 2.3% | ||
| Q1 24 | 2.0% | 2.6% |
| Q4 25 | — | 0.71× | ||
| Q3 25 | — | 2.30× | ||
| Q2 25 | 21.55× | 1.88× | ||
| Q1 25 | -0.06× | — | ||
| Q4 24 | — | 1.80× | ||
| Q3 24 | 0.45× | 1.97× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | 0.06× | 1.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
SGI
| Mattress Firm Segment | $892.1M | 48% |
| Tempur Sealy North America Segment | $620.5M | 33% |
| Tempur Sealy International Segment | $355.8M | 19% |
